Maypharm Unveils Revolutionary Hybrid Filler, Hyalmass Aqua-Exosome: The Future of Skin Hydration and Regeneration

December 30, 2024 04:00 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
  • Introducing Hyaluronic Acid, Exosomes, and PDRN

SEOUL, South Korea, Dec. 30, 2024 /PRNewswire/ -- Maypharm Co., Ltd., a leading innovator in medical and dermo-cosmetic products, proudly introduces the global launch of Hyalmass Aqua-Exosome, a groundbreaking hybrid mesotherapy filler designed to redefine skin hydration and revitalization.

Hyalmass Aqua-Exosome
Hyalmass Aqua-Exosome

Maypharm Co., Ltd. is set to revolutionize the aesthetic industry with the introduction of Hyalmass Aqua-Exosome. This cutting-edge hybrid filler combines the power of hyaluronic acid, exosomes, and PDRN to maximize skin hydration, elasticity, and regeneration.

Hyalmass Aqua-Exosome is a breakthrough in aesthetic innovation, offering unmatched benefits for skin health and rejuvenation. Unlike traditional hydration fillers that focus solely on moisture, Hyalmass Aqua-Exosome elevates skin health standards by leveraging the regenerative potential of exosomes and PDRN.

"At Maypharm, we are committed to pushing the boundaries of aesthetic technology to deliver transformative results for our customers," says KWON JONGWOOK, CEO of Maypharm Co., Ltd. "With Hyalmass Aqua-Exosome, we aim to provide a comprehensive solution that not only hydrates the skin but also promotes long-term elasticity and regeneration."

Hyalmass Aqua-Exosome
Hyalmass Aqua-Exosome

Key Features of Hyalmass Aqua-Exosome:

  1. Advanced Formulation: Hyalmass Aqua-Exosome contains a unique blend of hyaluronic acid, exosomes derived from human stem cell conditioned media and plant sources, and PDRN (polydeoxyribonucleotide). This innovative combination maximizes skin regeneration and elasticity, resulting in visibly smoother and more radiant skin.
  2. Prefilled Syringes: Hyalmass Aqua-Exosome comes conveniently packaged in prefilled syringes, ensuring optimal hygiene and safety for both patients and practitioners.
  3. Long-lasting Efficacy: Utilizing high-purity, high-molecular-weight raw materials, Hyalmass Aqua-Exosome delivers long-lasting benefits to the skin, enhancing its viscoelasticity and overall vitality.
  4. Stimulates Fibroblasts: The primary ingredient in Hyalmass Aqua-Exosome stimulates fibroblasts to promote collagen and elastin production, leading to improved skin elasticity, anti-aging effects, and enhanced skin regeneration.

In comparison to traditional hydration fillers, Hyalmass Aqua-Exosome emerges as the superior choice. While conventional hydration fillers deliver quick moisture, their benefits are often limited to hydration alone, offering minimal regenerative effects. In contrast, Hyalmass Aqua-Exosome not only provides immediate hydration with hyaluronic acid but also promotes long-term skin elasticity and regeneration through the inclusion of exosomes and PDRN. This innovative formulation leads to a significant overall improvement in skin condition, positioning Hyalmass Aqua-Exosome as a revolutionary advancement in aesthetics.

With the launch of Hyalmass Aqua-Exosome, Maypharm Co., Ltd. continues its commitment to innovation, excellence, and customer satisfaction in the field of cosmetic medicine and dermo-cosmetic products. Experience the future of medical and aesthetics with Hyalmass Aqua-Exosome and unlock the secret to radiant, youthful-looking skin.

Partnership with Beauty Factory:

The production of Hyalmass Aqua-Exosome is supported by Beauty Factory, a leading Korean medical aesthetics manufacturer renowned for its commitment to innovation and quality. While Maypharm is responsible for the global distribution and commercialization of Hyalmass Aqua-Exosome, Beauty Factory's advanced manufacturing capabilities ensure that this product meets the highest industry standards.

Beauty Factory
Beauty Factory

Beauty Factory operates state-of-the-art facilities that comply with international Good Manufacturing Practice (GMP) guidelines. With their proprietary HALO manufacturing technology, developed through partnerships with prestigious academic institutions like KINS Lab at Seoul National University and the Biomaterial Synthesis Lab at Sookmyung University, Beauty Factory maintains its leadership in medical aesthetics. Their collaborations with renowned global R&D partners in Poland and Germany further enhance the scientific and technological advancements that support the creation of Hyalmass Aqua-Exosome.

Quality Control at Beauty Factory:

Beauty Factory's rigorous quality control process ensures that every product, including Hyalmass Aqua-Exosome, meets the highest standards for safety and efficacy. With a 7-step quality control (QC) system in place, Beauty Factory guarantees that all products undergo meticulous testing to ensure consistent and reliable performance across all applications.

Maypharm, in collaboration with Beauty Factory, is excited to introduce a product that combines cutting-edge technology and advanced formulation to not only provide immediate skin hydration but also support long-term skin health and rejuvenation, establishing a new standard in the aesthetic industry.

For more information about Hyalmass Aqua-Exosome and other products from Maypharm Co., Ltd., please visit www.maypharm.net or contact [email protected].


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.